Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (25689)	9/24/1998 1:01:00 AM
From: Cheryl Galt	Read Replies (2) \| Respond to of 32384

>> Cheryl, For your [Seragen] notebook: (this should go well with your cup of coffee this morning) << --- J.D. Are you referring to "diptheria toxin" and "E.Coli?" --- Thank you, but I prefer cream. >> PP. 108 Seragen Proxy/Prospectus 7/14/98 -- Manufacturing << ---------------------------------------------------------------- Thanks for all your digging, J.D. And I really MEAN that. I'm taking this "due diligence seriously. No more sloppy shareholdering for me! My notes are almost done, for now --- on the Risks aspect. I like all the Risks neatly cataloged, because I do NOT want to be blindsided unnecessarily. With this accomplished, I now can Expect the best, but be fully prepared for the worst. Now to collect the Reward data. Lead on Skeeter! ------------------------------------------------- But first, to make sure this Risk stuff is done: 1) J.D., Thanks for noting the SOURCE of this information, in the 7/14/98 Prospectus. 2) Thanks for the outstanding shares data. 3) The writeup from the Seragen Prospectus clears up several points for me, and opens two new question -- as you yourself seem to note, by the bolding in your post. Points now cleared up: o Manufacturing WAS done by Seragen in it's own facilities o Then it sold those facilities to Marathon, and continued to use them o Seragen "regularly contracts with .. firms for certain quality control testing ---- and for fill-finish servises" ------- As of July 1, 1998, Lilly is Seragen's fill/finish contractor. ---------From another document, I know Lilly committed to this for 5 years. ------------------------------------------ TWO Uncertainties: Watch for answers to these ... 1) Seragen BELIEVES that its Fusion Proteins can be produced in COMMERCIAL quantities 2) ....In order for this manufacturing facility to produce material that can be marketed, it must be inspected and licensed by the FDA. If anyone calls IR, please ask about these two items. Cheryl PS Nice volume today. I'll be watching volume closely ...